Memory Disorders
Disturbances in registering an impression, in the retention of an acquired impression, or in the recall of an impression. Memory impairments are associated with DEMENTIA; CRANIOCEREBRAL TRAUMA; ENCEPHALITIS; ALCOHOLISM (see also ALCOHOL AMNESTIC DISORDER); SCHIZOPHRENIA; and other conditions.
Subtype terms (2)
More specific conditions that are subtypes of Memory Disorders in the MeSH hierarchy.
- Amnesia
11 drugs (9 approved, 2 experimental)
- Korsakoff Syndrome
1 drug approved
Drugs by status
Approved for this indication (1)
Phase 4 trials (14)
Phase 2 trials (21)
Phase 1 trials (13)
Other trials (37)
- piracetam
- urea
- cocoa bean
- methylphenidate
- linseed oil
- levodopa
- carbidopa
- krill oil
- dronabinol
- propranolol
- resveratrol
- clonidine
- strawberry
- bifidobacterium longum
- blueberry allergenic extract
- coffee
- flavanol
- flax
- hx106
- mango
- deer bone extract
- phytoserm
- lactobacillus helveticus
- raspberry
- tremella fuciformis
- domperidone
- corn
- coriander
- yohimbine
- minocycline
- +7 more
Organizations
Organization Involved with Phase 4 Indications (14)
- Eisai
- Pfizer
- Ipsen
- Enzymotec
- National Institute of Mental Health (NIMH)
- National Institute on Aging (NIA)
- Harvard University
- Hoosier Cancer Research Network
- Medical University of Gdansk
- Tel Aviv University
- University of California, Los Angeles
- The New England Center for Headache
- Johnson and Johnson
- The University of Texas, Dallas
Organization Involved with Phase 3 Indications (11)
Organization Involved with Phase 2 Indications (12)
Organization Involved with Phase 1 Indications (4)
Organization Involved with Other Experimental Indications (12)